Driving discoveries and innovative treatments for childhood cancer and other diseases. Ranked #3 by USNWR. #StJude #StJudeResearch
Memphis, Tenn.
Joined November 2011
- Tweets10.2K
- Following2.1K
- Followers33K
- Likes7.5K
St. Jude researchers and their collaborators found that mutations present in B-cell acute lymphoblastic leukemia at diagnosis can predict relapse risk, with their significance varying by leukemia subtype. The findings provide a framework to better identify patients at higher risk of relapse and could eventually help clinicians tailor treatment intensity at diagnosis to prevent recurrence while avoiding unnecessary treatment. bit.ly/4sFk50H
Researchers identified how the methyltransferase METTL13 alters the translation factor eEF1A, revealing mechanisms that help drive cancer development and treatment resistance. The findings highlight a potential therapeutic strategy to inhibit KRAS production in tumors. bit.ly/3Wd2KQu
Anjana Nityanandam, PhD, came to St. Jude in 2016 to build the Human Neural Organoid Laboratory. Today, the lab develops human brain organoids that help researchers study development, disease and potential approaches to treatment.
Learn more: bit.ly/4zZswGw
Since Mongolia received its first shipment through the Global Platform for Access to Childhood Cancer Medicines in February 2025, the National Centre for Maternal and Child Health has reported no medicine shortages or treatment interruptions.
St. Jude, World Health Organization and partners worked with Mongolia’s Ministry of Health and local health care teams to review access to 35 essential medicines, update clinical protocols and chemotherapy procedures, train health care professionals, and establish safer systems for preparing treatments.
These efforts are helping children receive quality-assured medicines and continue treatment in Mongolia while strengthening the systems needed to sustain childhood cancer care.
Read how the Global Platform is bringing greater stability to children, families and health care teams in Mongolia: bit.ly/4jJQzV8
Scientists identified the COMPASS pathway as critical to regulatory T cells’ ability to prevent harmful immune responses to gut bacteria. The findings reveal a specialized role for a broadly expressed gene-regulatory pathway and suggest that revisiting overlooked genetic variants in specific T-cell subtypes could uncover mechanisms behind inflammatory bowel disease, food allergies and other disorders. bit.ly/47N7cYE
St. Jude has been named the No. 1 employer in the nation on @Forbes America’s Dream Employers 2027 list. The ranking combined feedback from college students with evaluations from employees, recognizing St. Jude as a destination for purpose-driven careers. bit.ly/48ereLQ
Join Adam Shlien, PhD, @SickKidsNews, in The Science of Childhood Cancer virtual lecture series Thursday. He will discuss molecular signatures that may improve childhood cancer diagnosis and inform treatment decisions.
Sign up now: bit.ly/4hkFOHz
St. Jude scientists identified a direct role for PARP1 in chromatin remodeling, revealing for the first time how the protein partially disassembles nucleosomes to make damaged DNA accessible for repair. The findings could lead to more targeted PARP1 inhibitors and potentially reduce treatment toxicity. bit.ly/4zRmFDb
St. Jude is offering a free livestream of the @NatureConf, “Accelerating Pediatric Cancer Innovation: From Research to Real-World Impact,” Nov. 11-12. Join from anywhere in the world and hear from a global community dedicated to advancing pediatric cancer care.
Register to watch: bit.ly/4spM3NO
Researchers identified a potential therapeutic vulnerability in a subset of osteosarcoma. In preclinical models, combining EP300 degradation with AKT inhibition slowed tumor growth and prolonged survival. The findings suggest a potential path toward more personalized treatment. bit.ly/3U3DwDt
Aseem Ansari, PhD, St. Jude Department of Chemical Biology & Therapeutics chair, will present Thursday in The Science of Childhood Cancer virtual lecture series. He will share how cell surface receptors can directly regulate genes in the nucleus and what it means for future therapies.
Register for his talk today: bit.ly/4hkFOHz
Charles W.M. Roberts, MD, PhD, and Carsten Bönnemann, MD, habil., have been elected to the @theNAMedicine, one of the highest honors in health and medicine. Their election recognizes contributions advancing scientific understanding and improving patient care.
Roberts, St. Jude president and CEO-elect, was recognized for advancing understanding of how disruptions to chromatin remodeling complexes contribute to cancer, helping lay the foundation for new FDA-approved and investigational therapies. bit.ly/4iuc6ji
Bönnemann was recognized for his contributions to precision medicine for neurogenetic and neuromuscular disorders. His work has advanced understanding of the genetic causes of diseases such as juvenile ALS and congenital muscular dystrophy while helping drive novel therapeutic approaches. bit.ly/480lfdp
Research from Suzanne Baker, PhD; Stacey Ogden, PhD; Lindsay Schwarz, PhD; and Jay Bikoff, PhD, reveals how development shapes brain tumors, organ formation, anxiety and movement, connecting molecular and cellular mechanisms with disease and potential therapeutic targets.
Schwarz mapped a stress-related brain circuit linking C1 neurons to a key brain region. Prolonged activation produced lasting anxiety-like behavior, while inhibition reduced it. bit.ly/4ycfmph
Bikoff linked a subgroup of spinal neurons, V1Pou6f2, to the speed of rhythmic movement. Loss of these neurons slowed locomotion without disrupting limb movements. bit.ly/4g1d58f
